MedCity News April 19, 2024
The FDA expanded the approval of Roche’s Alecensa to include adjuvant treatment of non-small cell lung cancer. The targeted therapy addresses cancers driven by the ALK genetic mutation.
A Roche cancer drug that treats lung cancer with a certain genetic signature now has an additional FDA approval that expands the applications of the blockbuster product.
The drug, Alecensa, is already approved as a first- and second-line treatment for non-small cell lung cancer (NSCLC). The latest approval for the drug permits its use as an adjuvant, a therapy used after the primary cancer treatment (usually surgery) to kill any remaining cancer cells and to reduce the risk of the disease’s return.
Alecensa is a tyrosine kinase inhibitor, a type of drug...
Today's Sponsors
Today's Sponsor